Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma ...
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and Ce ...
Gas-powered counter-UAS platform completes airframe build and enters systems integration; initial flight testing planned for Q3 2026 ZenaTech, Inc. (NASDAQ:ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results